Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ALENDRONATE FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
Autore:
SAAG KG; EMKEY R; SCHNITZER TJ; BROWN JP; HAWKINS F; GOEMAERE S; THAMSBORG G; LIBERMAN UA; DELMAS PD; MALICE MP; CZACHUR M; DAIFOTIS AG;
Indirizzi:
UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,DIV RHEUMATOL,200 HAWKINS DR IOWA CITY IA 52242 UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV RHEUMATOL IOWA CITY IA 00000 UNIV IOWA,COLL MED,DEPT PREVENT MED & ENVIRONM HLTH IOWA CITY IA 00000 BONE RES CTR W READING PA 00000 CHU QUEBEC ST FOY PQ CANADA NORTHWESTERN UNIV CHICAGO IL 60611 HOSP 12 OCTUBRE,SERV ENDOCRINOL E-28041 MADRID SPAIN UNIV HOSP GHENT GHENT BELGIUM KOMMUNE HOSP COPENHAGEN,OSTEOPOROSE CENTRET COPENHAGEN DENMARK BEILINSON MED CTR PETAH TIQWA ISRAEL HOP EDOUARD HERRIOT LYON FRANCE MERCK RES LABS RAHWAY NJ 00000
Titolo Testata:
The New England journal of medicine
fascicolo: 5, volume: 339, anno: 1998,
pagine: 292 - 299
SICI:
0028-4793(1998)339:5<292:AFTPAT>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORTICOSTEROID-INDUCED OSTEOPOROSIS; RHEUMATOID-ARTHRITIS PATIENTS; INDUCED BONE LOSS; VERTEBRAL FRACTURES; INDUCED OSTEOPENIA; CONTROLLED TRIAL; CALCIUM; ETIDRONATE; CALCITONIN; SECONDARY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
34
Recensione:
Indirizzi per estratti:
Citazione:
K.G. Saag et al., "ALENDRONATE FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS", The New England journal of medicine, 339(5), 1998, pp. 292-299

Abstract

Background Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment. Methods We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures. Results The mean (+/-SE) bone density of the lumbar spine increased by 2.1+/-0.3 percent and 2.9+/-0.3 percent, respectively, in the groups that received 5 and 10 mg of alendronate per day (P<0.001) and decreased by 0.4+/-0.3 percent in the placebo group. The femoral-neck bone density increased by 1.2+/-0.4 percent and 1.0+/-0.4 percent inthe respective alendronate groups (P<0.01) and decreased by 1.2+/-0.4percent in the placebo group (P<0.01). The bone density of the trochanter and total body also increased significantly in the patients treated with alendronate. There were proportionally fewer new vertebral fractures in the alendronate groups (overall incidence, 2.3 percent) thanin the placebo group (3.7 percent) (relative risk, 0.6; 95 percent confidence interval, 0.1 to 4.4). Markers of bone turnover decreased significantly in the alendronate groups (P<0.001). There were no differences in serious adverse effects among the three groups, but there was asmall increase in nonserious upper gastrointestinal effects in the group receiving 10 mg of alendronate. Conclusions Alendronate increases bone density in patients receiving glucocorticoid therapy. (N Engl J Med 1998;339:292-9. ) (C)1998, Massachusetts Medical Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 11:01:30